Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M7224 | RS 504393 | RS 504393 is a highly selective CCR2 chemokine receptor antagonist. |
| M50164 | CM369 | CM369 is a potential first-of-its-kind (first-in-class) anti-chemokine receptor 8 (CCR8) monoclonal antibody that binds specifically to CCR8 on Treg and removes immunosuppressive Treg through ADCC action to relieve tumor suppression in the TME.CM369 can be used in studies related to advanced solid tumors. |
| M50163 | BGB-A3055 | BGB-A3055 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50162 | AMG-355 | AMG-355 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50161 | ABBV-514 | ABBV-514 is a CCR8 inhibitor that can be used in studies related to respiratory diseases and tumors. |
| M50160 | SRF-114 | SRF-114 is a human IgG1 anti-CCR8 monoclonal antibody that targets tumor Treg cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC) through activation of NK cells, resulting in selective depletion of immunosuppressive tumor T regulatory cells (Tregs) while preserving peripheral Tregs. It can be used for tumor-related studies. |
| M50159 | S-531011 | S-531011 is a novel anti-human IgG1 antibody that exhibits in vitro antibody-dependent cytotoxicity against CCR8-expressing cells and neutralizing activity against the CCL1-CCR8 signaling pathway. It can be used in studies related to solid tumors. |
| M50158 | LM-108 | LM-108 is a novel anti-CCR8 monoclonal antibody that efficiently eliminates tumor-associated Tregs in a mouse model through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Tregs, showing potent anti-tumor activity, and can be used for tumor-related studies. |
| M49638 | CKLF1-C27 TFA | CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. |
| M49637 | CKLF1-C27 | CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. |
| M49447 | GS-1811 | GS-1811 is a monoclonal antibody targeting CCR8 that selectively removes tumor-infiltrating T regulatory cells with immunosuppressive effects in the tumor microenvironment, and can be used in studies related to solid tumors. |
| M49444 | BAY-3375968 | BAY-3375968 is a monoclonal antibody targeting the CCR8 receptor that selectively reduces CCR8-positive Tregs through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and can be used in studies related to solid tumors. |
| M49442 | BMS-986340 | BMS-986340 is a human immunoglobulin G1 (IgG1) non-fucosylated (NF) monoclonal antibody to CCR8 that targets, binds to, and blocks CCR8 activity on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in tumor microenvironments (TMEs) and prevents chemokine ligand (CCL1-CCR8)-mediated signaling. |
| M41795 | CCR5 antagonist 5 | CCR5 antagonist 5 is a CCR5 antagonist. |
| M41794 | SB-649701 | SB-649701 is a potent human CCR8 antagonist, with a pIC50 of 7.7. |
| M40814 | Zelnecirnon | Zelnecirnon is an orally active CCR4 inhibitor that inhibits the recruitment of Th2 inflammatory immune cells to inflamed tissues and may be used in studies related to atopic dermatitis and asthma. |
| M40607 | CCR7 Ligand 1 | CCR7 Ligand 1 (CCR7-Cmp2105) is a human CC chemokine receptor 7 (CCR7) variant ligand and a potent intracellular CCR7 receptor variant antagonist with a Kd value of 3 nM. In addition, CCR7 Ligand 1 also inhibited CCL19 activation with an IC50 value of 7.3 μM. |
| M40560 | Tivumecirnon | Tivumecirnon is a potent CCR4 small molecule antagonist with antitumor activity that blocks regulatory T cells that interfere with an effective antitumor immune response. It can be used in melanoma related studies. |
| M40551 | Nifeviroc | Nifeviroc (nifeviroc) is an orally active CCR5 antagonist for use in HIV-1 infection studies. |
| M30699 | MK-0812 Succinate | MK-0812 Succinate is a potent and selective CCR2 antagonist with high affinity at CCR2. |
| M30691 | ML604086 | ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
